Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Till

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 31, 2025
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell LymphomaM Ebadi, X Fan, G Schoch, et al.
British Journal of Haematology|February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemiaChaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.
Cancer Research|September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell CancersDamian J Green, Shani L Frayo, Yukang Lin, et al.
British Journal of Haematology|May 3, 2019
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United StatesMarcus Geer, Emily Roberts, Maryann Shango, et al.
Nature Communications|April 6, 2026
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody responseStosh Ozog, Elizabeth M Krantz, Karyn Tindbaek, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaS A Graf, P A Stevenson, L A Holmberg, et al.
The Lancet. Oncology|July 6, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trialAndrew J Cowan, Margot J Pont, Blythe D Sather, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 31, 2025
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell LymphomaM Ebadi, X Fan, G Schoch, et al.
British Journal of Haematology|February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemiaChaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.
Cancer Research|September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell CancersDamian J Green, Shani L Frayo, Yukang Lin, et al.
British Journal of Haematology|May 3, 2019
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United StatesMarcus Geer, Emily Roberts, Maryann Shango, et al.
Nature Communications|April 6, 2026
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody responseStosh Ozog, Elizabeth M Krantz, Karyn Tindbaek, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaS A Graf, P A Stevenson, L A Holmberg, et al.
The Lancet. Oncology|July 6, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trialAndrew J Cowan, Margot J Pont, Blythe D Sather, et al.
Pageof 12